According to Novartis (NVS), “Entresto is a combination of a neprilysin inhibitor (sacubitril) and an angiotensin receptor blocker (valsartan) and reduces the strain on the failing heart ...

About Entresto Entresto exhibits the mechanism of action of an Angiotensin Receptor Neprilysin Inhibitor that reduces the strain on the failing heart.

During the first three months of the year, Entresto sales jetted upward by 39% to $789 million. It also joined the triumvirate of Novartis' top-selling drugs last year, generating $2.5 billion in ...

FDA on Tuesday granted Entresto, a combination of sacubitril and valsartan, an indication to treat patients with heart failure (HF) with preserved ejection fraction (HFpEF), the first time a ...

The new study aims to boost Entresto’s use in HFrEF patients where a 2014 study (PARADIGM-HF), conducted in patients not sick enough to need hospitalisation, has failed.

Novartis failed to convince a federal court to block generic drugmaker MSN Pharmaceuticals from launching its own version of Novartis' blockbuster heart-failure drug Entresto, according to a court ...